The Ohio State University Corporate Engagement Office

Back to All Technologies

Multi-Functional Drug Delivery Nanodevice for Precision Medicine

Clinical Area
Life & Health Sciences
Genetic Disorders
Infectious Disease
Oncology
Drug Delivery
Therapeutics
Nucleic Acid-Based & AAV
Vaccines
Other
College
College of Engineering (COE)
Researchers
Castro, Carlos
Byrd, John
Halley, Patrick
Lucas, Christopher
Licensing Manager
He, Panqing
614-247-4481
he.17@osu.edu

T2018-305 A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.

The Technology

This novel therapeutic approach leverages structural nanotechnology to create a DNA nanostructure that acts as a customizable delivery vehicle for therapeutic molecules. The technology allows for a highly tunable and customizable multi-functional drug delivery platform that incorporates interchangeable i) small molecule therapeutics, ii) therapeutic oligonucleotides, and iii) targeting moieties on a single DNA-based nanostructure to specifically target and destroy tumor cells, while leaving healthy tissue unharmed.

The folded DNA nanoparticle was shown to deliver clinically relevant dosages of daunorubicin in a human Acute Myeloid Leukemia multi-drug resistant cell line and refined drug release profiles. Combined with its fast self-assembly and stability in physiological conditions, this DNA nanostructure could be implemented to deliver a wide-range of therapeutic agents and/or nucleic acids in a targetable manner.

Benefits/Advantages

  • Rapid self-assembly of stable DNA origami nanostructures
  • Scalable for commercial production
  • Carrier for small molecule drugs, therapeutic oligonucleotides, and/or targeting/therapeutic antibodies
  • Refined control of molecular placement for multi-functional modular devices (e.g. simultaneous, co-localized distribution) of therapeutic oligonulceotides and targeting molecules against a specific tumor antigen
  • Refined loading of therapeutic agents
  • Biocompatible

Stage of Development

  • Pre-clinical
  • in vivo data in xenograft model of AML; data includes safety, immunogenicity, pharmakokinetics, distribution

Commercialization Opportunties

  • Precision medicine through antibody-targeting
  • Customizable drug delivery platform
  • Disease agnostic